Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis-Reference-Cited by-同舟云学术

Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis

Published:2018-11 Issue: Volume:103 Page:78-87
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Feyerabend Susan,Saad Fred,Li Tracy,Ito Tetsuro,Diels Joris,Van Sanden Suzy,De Porre Peter,Roiz Julie,Abogunrin Seye,Koufopoulou Maria,Fizazi Karim

Funder

Janssen Global Services, LLC

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference34 articles.

1. Understanding heterogeneity of treatment effect in prostate cancer;Aly;Curr Opin Oncol,2015

2. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer;Fizazi;N Engl J Med,2017

3. Abiraterone for prostate cancer not previously treated with hormone therapy;James;N Engl J Med,2017

4. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis;Rydzewska;Eur J Cancer,2017

5. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial;Kyriakopoulos;J Clin Oncol,2018

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Japanese clinical practice guidelines for prostate cancer 2023;International Journal of Urology;2024-07-30

2. Efficacy and safety of triple or dual therapies for metastatic hormone-sensitive prostate cancer: a systematic review and Bayesian network meta-analysis;Future Oncology;2024-06-19

3. Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes;JAMA Oncology;2024-06-01

4. Identifying Suitable Patients for Overcoming Androgen Deprivation Monotherapy in De Novo Metastatic Hormone-Sensitive Prostate Cancer;Journal of Personalized Medicine;2024-05-13

5. Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer;Current Oncology Reports;2024-04-09